Disulfiram and copper combination therapy targets NPL4, cancer stem cells and extends survival in a medulloblastoma model

Medulloblastoma (MB) is the most common brain malignancy in children, and is still responsible for significant mortality and morbidity. The aim of this study was to assess the safety and efficacy of Disulfiram (DSF), an FDA-approved inhibitor of Aldehyde-Dehydrogenase (ALDH), and Copper (Cu++) in hu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2021-11, Vol.16 (11), p.e0251957-e0251957
Hauptverfasser:	Serra, Riccardo, Zhao, Tianna, Huq, Sakibul, Gorelick, Noah Leviton, Casaos, Joshua, Cecia, Arba, Mangraviti, Antonella, Eberhart, Charles, Bai, Renyuan, Olivi, Alessandro, Brem, Henry, Jackson, Eric M, Tyler, Betty
Format:	Artikel
Sprache:	eng
Schlagworte:	Aldehyde Dehydrogenase - metabolism Aldehydes Animals Apoptosis Apoptosis - drug effects Biocompatibility Biology and Life Sciences Brain cancer Brain Neoplasms - metabolism Brain Neoplasms - pathology Brain research Brain tumors Cancer Cancer therapies Care and treatment Caspase-3 Cell Cycle - drug effects Cell death Cell Proliferation - drug effects Cell survival Combination therapy Copper Copper - pharmacology Cytometry Cytotoxicity Dehydrogenases Deoxyribonucleic acid Diagnosis Disulfiram Disulfiram - pharmacology DNA DNA damage Glial fibrillary acidic protein Health aspects Immunofluorescence Immunohistochemistry Laboratories Localization Medical prognosis Medicine Medicine and Health Sciences Medulloblastoma Medulloblastoma - metabolism Medulloblastoma - pathology Molecular modelling Morbidity Neoplastic Stem Cells - drug effects Neoplastic Stem Cells - metabolism Neoplastic Stem Cells - pathology Nestin Neurosurgery Nuclear safety Pediatrics Proteins Radiation Research funding Stem cells Survival Toxicity Tumors Xenografts Xenotransplantation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!